Latest Regulatory Filings News

First Au Limited has completed the initial tranche of its $1.5 million private placement, issuing over 4 million shares, while the much larger second tranche awaits shareholder approval at the upcoming AGM.

PointsBet Holdings has dismissed allegations from Betr Entertainment regarding vote exclusion in its recent Scheme of Arrangement meeting, confirming the scheme’s approval and setting the stage for a crucial court hearing.

Electro Optic Systems Holdings Limited has explained a delayed filing of a director interest notice as an administrative oversight, affirming its compliance processes remain robust.

Cleo Diagnostics has gained approval to access the prestigious PLCO biobank, a move set to strengthen its FDA submission and accelerate development of its ovarian cancer diagnostic tests.

Solis Minerals has voluntarily delisted from the TSX Venture Exchange to concentrate on its primary ASX listing, prompting changes to its ASX waivers and financial reporting calendar.

North Stawell Minerals has completed a $1 million placement, issuing over 33 million shares to fund its exploration efforts in Victoria's Stawell Mineralised Corridor.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Findi Limited has appointed DAM Capital and Ambit as lead managers for the IPO of its Indian subsidiary, Transaction Solutions International, targeting a valuation near A$900 million and a 2026 listing.

Brookside Energy has expanded its SWISH Play acreage in Oklahoma's Anadarko Basin by adding a fifth Drilling Spacing Unit, increasing its high-impact drilling inventory by over a quarter. This move strengthens its development pipeline ahead of a planned NYSE listing.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Shift4 Payments, LLC has entered into a definitive scheme implementation agreement to acquire Smartpay Holdings Limited at NZ$1.20 per share, subject to regulatory and shareholder approvals. The transaction outlines a detailed timetable and conditions, including Overseas Investment Office consent and court sanction.

Kinterra Capital has applied to the Takeovers Panel to halt New World Resources’ $10 million placement, arguing it could block rival bids amid an ongoing takeover dispute.